The deal will not be finalized until approved by Exact Sciences’ shareholders. With it, Abbott gains control of new diagnostic tools, including a popular at-home test for colorectal cancer.

No other heart or transplant services at the nonprofit hospital should be impacted by this temporary shift in care. 

The collaboration allows providers to order diagnostic tests and then receive results directly in Epic.